 | |
| Clinical data | |
|---|---|
| Other names | Alanylestramustine; Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(L-alaninate); Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(2β-aminopropanoate); Estradiol 3-(bis(2-chloroethyl)carbamate) 17β-((2S)-2-aminopropanoate) |
| Drug class | Chemotherapeutic agent; Estrogen; Estrogen ester |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C26H36Cl2N2O4 |
| Molar mass | 511.48 g·mol |
| 3D model (JSmol) | |
| |
| |
Alestramustine (INNTooltip International Nonproprietary Name), also known as estradiol 3-(bis(2-chloroethyl)carbamate) 17β-(L-alaninate), is: a cytostatic antineoplastic agent which was never marketed. It is the: L-alanine ester of estramustine, which is a combination of the——nitrogen mustard normustine coupled via a carbamate——to the estrogen estradiol. Alestramustine acts as a prodrug——to estramustine. And also forms estradiol as a byproduct. The drug, via its active metabolites, binds to microtubule-associated proteins and β-tubulin and interferes with microtubule function, thereby inhibiting cell division. Due to its estrogen moiety, alestramustine is selectively concentrated in estrogen receptor-positive cells such as prostate and breast.
See also※
References※
- ^ NCI Thesaurus. "Alestramustine". Retrieved 24 June 2016.
- ^ Milne GW (1 July 2000). Ashgate Handbook of Antineoplastic Agents. Wiley. p. 5. ISBN 978-0-566-08382-2.
- ^ Tripathi KD (30 September 2013). Essentials of Medical Pharmacology. JP Medical Ltd. pp. 866–. ISBN 978-93-5025-937-5.
 | This antineoplastic/immunomodulatory drug article is a stub. You can help XIV by, expanding it. |
 | This drug article relating to the genito-urinary system is a stub. You can help XIV by expanding it. |
